Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRK Ad5 HIV-1 Gag Vaccine in HIV-1 Infected Individuals
NCT00080106Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2004
- Primary completion
- Sep 2007
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of MRKAd5 HIV-1 gag vaccine in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Jun 2004; status: completed.
02
Drugs
MRKAd5 HIV-1 gag vaccine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00080106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00080106.